A Long-Term Study of Rovalpituzumab Tesirine

Inclusion Criteria

• Subject had enrolled, participated in, and received at least 1 dose of rovalpituzumab tesirine in a parent study.
• Additional eligibility criterion for Arm A: subjects who discontinued the study drug in the parent study have completed the treatment emergent adverse event reporting window. For subjects who elect optional retreatment in Arm A, must meet additional criteria before receiving rovalpituzumab tesirine retreatment including:
• Tolerated their initial 2 doses of rovalpituzumab tesirine.
• Achieved clinical benefit as defined by stable disease or better, and is determined that the subject would potentially benefit from additional treatment.
• Experienced radiographic disease progression at least 12 weeks after the second dose of rovalpituzumab tesirine.
• Received no other systemic anti-cancer therapy after rovalpituzumab tesirine treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate hematologic, kidney, and liver function, per protocol.
• In subjects with central nervous system (CNS) metastases, documentation of stable or improved status as described in the protocol.

Exclusion Criteria

• Subjects not previously enrolled in a rovalpituzumab tesirine study.